ion of the
purchase price to the assets acquired and liabilities assumed, based on their
fair values.
Book Value Fair Value Fair Value
Adjustments
US$M US$M US$M
____________ ___________ ___________
Non-current assets:
Other intangible assets, net
- Intellectual property -
developed technology - 1,133.3 1,133.3
- Favourable manufacturing
contracts - 9.2 9.2
- In process research and
development - 1,943.3 1,943.3
Property, plant and equipment, net 2.6 (1.8) 0.8
Deferred tax assets, non-current 1.1 52.4 53.5
Current assets:
Inventories 4.8 6.6 11.4
Accounts receivable, net 0.3 - 0.3
Prepaid expenses and other
current assets 2.4 (2.2) 0.2
Purchased call option 141.8 - 141.8
Short-term investments 55.8 - 55.8
Cash and cash equivalents 74.9 - 74.9
Non-current liabilities:
Sold warrants (133.0) 133.0 -
Deferred income, non-current (59.5) 59.5 -
Deferred tax liability,
non-current (1.1) (1,109.5) (1,110.6)
Current liabilities:
Convertible loan notes (279.4) - (279.4)
Accounts payable and accrued
expenses (33.3) 1.6 (31.7)<
'/>"/>
SOURCE Shire plc Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 Related biology technology :1.
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%2.
Shire plc: Correction Re Website3.
Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome4.
Shire Engages Palio5.
Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter6.
FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients7.
Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation8.
Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-10019.
Shire plc: Board Changes10.
David Mott Appointed Non Executive Director at Shire11.
Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007